Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
REVIEW
Year : 2015  |  Volume : 11  |  Issue : 3  |  Page : 508-513

Current and emerging breast cancer biomarkers


Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering, Faisalabad 38000, Pakistan

Date of Web Publication9-Oct-2015

Correspondence Address:
Maryam Sana
National Institute for Biotechnology and Genetic Engineering, Faisalabad 38000
Pakistan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.163698

Rights and Permissions
 > Abstract 

Breast cancer treatment has experienced several advancements in the past few decades with the discovery of specific predictive and prognostic biomarkers that make possible the application of individualized therapies. In addition to traditional prognostic factors of breast carcinoma, molecular biomarkers have played a significant role in tumor prediction and treatment. The most frequent genetic alterations of breast cancer are gained along chromosome 1q, 8q, 17q, 20q, and 11q and losses along 8p, 13q, 16q, 18q, and 11q. Interestingly, many of these chromosomal fragments harbor known proto oncogenes or tumor suppressor genes such as BRCA1, BRCA2, p53, HER2-neu, cyclin D1, and cyclin E, which are briefly described in this review.

Keywords: Biomarkers, breast cancer, individualized therapy, mutation, prognostic and predictive factors


How to cite this article:
Sana M, Malik HJ. Current and emerging breast cancer biomarkers. J Can Res Ther 2015;11:508-13

How to cite this URL:
Sana M, Malik HJ. Current and emerging breast cancer biomarkers. J Can Res Ther [serial online] 2015 [cited 2019 Dec 11];11:508-13. Available from: http://www.cancerjournal.net/text.asp?2015/11/3/508/163698


 > Introduction Top


Breast carcinoma is highly heterogeneous disorder both etiologically and genetically. In 2008, approximately 1.38 million new breast cancer cases were diagnosed that commonly occurring cancer worldwide. In Eastern Africa, the incidence rate of breast cancer varies from 19.3/100,000 women and in the developed regions of the world (except in Japan), the incidence rate is very high that is 80/100,000 women. [1]

Incidence rates of breast cancer in most regions of the world especially in the developing nations are increasing, like incidence rate of breast cancer in Pakistan is 50.1/100,000 women per year. [2],[3]

Although still in the early stages of research, molecular breast cancer subtypes may become useful in planning treatment and developing new therapies. Most of the studies divide breast cancer into four major molecular subtypes as shown in [Table 1]. [4]
Table 1: Common profiles of breast cancer subtype

Click here to view


In the last 50 years, despite efforts to limit the occurrence of cancer globally, breast cancer has become the leading cause of death in women and rank second in cancer-related mortality. Early stage diagnosis is necessary for the management of this high-risk cancer, which requires sensitive and specific biomarkers as a marker for current or future disease state. [5]

A biomarker is a feature that is objectively evaluated and measured for the indication of pathogenic processes, normal biological processes, and pharmacologic responses to treatment. It is a biological indicator that detects molecular changes in the tissue and fluids of the body that associated with the disease. [6]

These biomarkers provide the biological material to estimate the risk of having and getting cancer, classify cancer and provide insights into prognosis and prediction, so have a therapeutic advantage. Cancer biomarkers may be changed in gene expression or mutation in some genes or methylation of promoter region of cancer-specific genes which caused a change in expression of proteins. [7]

Many potential prognostic and predictive biomarkers for breast cancer have been investigated, in the past few decades. With the progression of new techniques for gene expression profiling, it revealed that in comparison to traditional prognostic factors, novel biological factors and molecular markers have more important roles. Some established and emerging biomarkers are discussed here.

Established biomarkers

p53

p53 is one of the mostly studied biomarkers for breast cancer. It is a transcription factor that regulates the cell cycle, so it acts as tumor suppressor. The gene is named Tp53 after the protein which it codes. It is present on the short arm of chromosome 17 (17p 31.1 ). The name p53 is due to its molecular mass. Mutation in the p53 genes causes the formation of proteins that could not quickly degraded as wild type protein, so it accumulates and could be analyzed by immunohistochemistry. [8],[9] The human p53 gene is a nuclear phosphoprotein composed of 393 amino acids that causes both repression and activation of gene expression by binding at many sites of chromatin. [10],[11] It has short half-life so maintained at low level in unarrested cells, but in stress conditions such as in case of DNA damage, it is stabilized by posttranslational modifications. It also plays an important role in stem cell biology. [12]

p53 contains two transactivation domains on its N-terminus that is TAD1 and TAD2, in which mutation causes inactivation of p53 completely as tumor suppressor. At C terminal, there is a tetramerization domain that directly interacts with single-stranded DNA. [10] Many different p53 protein isoforms are encoded by human p53 gene that is p53α, p53β, p53γ, ∆133p53, ∆133p53β, ∆133p53ɤ, and ∆ 40p53. These isoforms are due to alternative splicing of intron 9 and 2, using alternative promoter in intron 4 and alternative initiation of translation. [13]

p53 controls cellular functions such as cell cycle control, DNA repair, apoptosis, angiogenesis, and cellular stress response through its target genes such as Mdm2, WAFI/CIPI, WIPI, BAX, PIG3, FASL, CSR, P21, etc. [14] Regulation of p53 occurs at different levels that are by postraslational modifications, by increasing the protein concentration and by cellular localization. [15]

After 15 years of discovery of p53, two genes were identified which were related to p53 that is p63 and p73. These genes have structurally and functionally similarity with p53 and work in a signaling network for controlling different cellular functions such as cell death, differentiation, and proliferation. [16] The Tp53 gene is found altered in breast carcinomas in approximately 20-40% of all cases depending upon tumor size and stage of the disease. It seems to be an early event in breast tumorigenesis. [17] About 75% of Tp53 mutations are missense, 9% are deletions and frame shift insertions, 7% are nonsense mutations, and 5% are silent mutations. Different mutant forms of p53 protein have different biological and functional effects. These mutations result in significant loss in transactivation capacity as well as in DNA binding activity. [9],[18]

HER2/neu

The most heterogeneous group of posttranslational modifications known in proteins is glycoproteins. Many prognostic and predictive biomarkers in cancer are glycoproteins in nature, for example, HER2-neu in case of breast cancer. The human epidermal growth factor receptor 2 gene is present on the long arm of chromosome 17 (17q 21.1 ). It encodes a receptor of molecular mass 185 kDa. These receptors are single pass transmembrane proteins and consist of intracellular tyrosine binding domain with various tyrosine phosphorylation sites and an extracellular domain for ligand binding and a cytoplasmic tail. [19] HER2 is a member of HER family, the other structurally related members of this family are HER1 (ErbB1 or epidermal growth factor receptor), HER3 (ErbB3), and HER4 (ErbB4). HER2-neu form heterodimers with other HER members preferably although it has no identified ligand. Major ligands of the other HER family receptors are transforming growth factor, epidermal growth factor (EGF), amphiregulin, heregulin, EGF, EPI, and NRG. [20],[21]

HER2 form homodimers and heterodimers and after dimerization, it induces different cellular functions such as cell growth, differentiation, and survival through different signaling cascade for example PLC gamma, MAPK, and PI3K. These pathways are influenced by pattern of dimerization. To prevent apoptosis and to promote cell proliferation, MAPK and PI3K are key signaling pathways. [22]

In normal cells, the number of HER2 receptor is 20,000 but in case of tumor, this number is increased up to 200,000 receptors. It will lead to aggressive form of breast cancer if left untreated. Twenty-five percent of all breast cancer cases are due to overexpression of HER2. [23] The HER2 positive breast cancer patients have more survival rate than patients without HER2 overexpression and significant apoptosis is induced in the breast cancer cells by the inhibition of HER2 overexpression. Both predictive and prognostic values of HER2 have been established. [24]

HER2 and Tp53 genes both are present on chromosome 17, HER2 on 17q 21.1 and Tp53 on 17p 13.1 . It is still unknown that how this proximity affects the interaction between these genes. There is a strong association between HER2 positive breast cancer and p53 mutations. Approximately, 71% of HER2 positive breast cancer patients contain mutated p53. If the patients have elevated level of HER2, indication for germline Tp53 mutation increased by almost seven-fold. [25]

Due to poor clinical outcome, HER2 overexpression represents an attractive target for therapeutic intervention. Trastuzumab is a monoclonal antibody, which targets the extracellular domain of the receptor and stops intracellular signaling thus prevent proliferation. It is approved as anti-HER2 antibody for the treatment of breast cancer patients with over-expression of HER2. [26] Among HER2 over-expressing tumor cells, HER2 protein levels are relatively homogenous, so in patients, anti-HER2 therapy targets most cancer cells. Nearly, all patients treated with trastuzumab ultimately experienced progression and disease recurrence. As trastuzumab binds with the extracellular domain of HER2, so physically it's binding with the receptor is prevented by shedding the extracellular domain which contains the trastuzumab binding site. [27]

BRCA1 and BRCA2

Approximately, 5-10% of breast cancers are hereditary, most of which are due to the mutations in tumor suppressor gene BRCA1 and BRCA2. BRCA1 is identified in 1994, located on chromosome 17q 21.31 which encodes a 220 kDa nuclear phosphoprotein. Much has been learned about the function of the BRCA1 in the past 10 years. BRCA1 spans about 110 kb of DNA by its 22 exons and contains tandem duplication of approximately 30 kb. [28] At its N-terminus, BRCA1 has a ring domain (amino acid 20-64). This domain mediates interaction of BRCA1 with other proteins and exhibit E3 ubiquitin ligase activity. At its C-terminus domain (BRCT), it is shared with other proteins which play an important role in maintaining genome integrity. [29] DNA repair and DNA response signaling functions of BRCA1 are associated with these domains. BRCA1 is a part of many super complexes which play an important role in different cellular functions like double strand break repair, activation of cell cycle checkpoints and activation of DNA damage response. Normally, BRCA1 form heterodimer with BARD1, which is also a RING/BRCT containing protein. BRCA1 is unstable in the absence of BRAD1 and rapidly degraded. [30]

BRCA2 is present on chromosome 13q 12.3 and contains 27 exons. In BRCA2, translation start sites present in exon 2 and in AT rich coding sequences. It encodes a 3418 residue protein and contains eight BRCT repeats. By the age of 70, high lifetime risk of breast cancer associated with BRCA1 and BRCA2 is 80% and 50% respectively. [31] In the subnuclear clusters, BRCA2 directly interact with RAD51 which is a key component of DNA damage repair via its C-terminus domain or BRC repeats, while in case of BRCA1 during this process, its activity is modulated by phosphorylation. If BRCA2 is defective, cells become hypersensitive to agents which break double stranded DNA or cross-link DNA strand. If cells contain nonfunctional BRCA2, repair of double strand breaks occur in error prone fashion. The errors result in chromosomal instability which is a feature of carcinogenesis. [32]

Up to 30% of the breast cancers are attributed to mutations in BRCA1 and BRCA2. In these mutations, three founder mutations are commonly encountered that is, c.5266dup (5382insC), c.68_69del (185delAG) in BRCA1, and c.5946del (6174delT) in BRCA2. It is highly unlikely that a different mutation will be found, in case if one of these mutations is not present. [33],[34]

Progesterone receptor

Progesterone receptor encoded by gene PGR and consists of 933 amino acids. It is located on chromosome 11q 21.1 . It is composed of three domains: A DNA binding domain, a modulating N-terminal domain and a ligand binding C-terminal domain. It is involved in cell-cell signaling, negative regulation of gene expression and transcription initiation from RNA polymerase II promoter. [35]

PR sequestered in a nonproductive form associated with cellular chaperones and other heat shock proteins, in the cells which lack the progesterone. In the absence of progesterone, the receptor is not able to control the transcription rate of its cognate promoters. In the presence of progesterone, PR undergoes many changes which involve dissociation from the heat shock protein complexes, conformational changes, phosphorylation, sumoylation, ubiquitination, dimerization, and nuclear translocation. These changes allow progesterone receptor to bind with progesterone response elements, which are present in the regulatory regions of target genes. This binding causes the upregulation of target gene transcription by recruitment of basal transcriptional machinery and co-activators. [36]

Progesterone has two receptors that are PRA and PRB, which are transcribed by the same gene using alternative promoter. Both these proteins are identical, but PRB is longer than PRA because it contains extra 164 amino acids on its N-terminal. PRA is a repressor of activity of PRB which is a major activator of transcription factors. [37] During tumorigenesis, there is a change in the ratio between PRA and PRB that is more PRA than PRB. PR expression is a marker for normal ER functions, and approximately 60% of breast cancer expresses PRA or PRB. Breast cancer patients contain steroid receptors show better prognosis and response to endocrine therapy than patients that lack these receptors. [38]


 > Emerging biomarkers Top


Ki-67

MKi-67 is a nuclear protein of molecular mass 359 kDa and commonly used for the detection and quantification of proliferating cells. Its expression is increased, associated with cell growth. It is commonly used as a diagnostic marker in various cancers because its expression reflects the cellular proliferation rate. [39]

Ki-67 gene is present on the long arm of chromosome 10 (10q 26.2 ). The complete sequence of cDNA encoding for the protein was published by Schluter in 1993. Alternative splicing results in two alternative mRNA species, encodes two isoforms of the protein. The small isoform has a calculated molecular mass of 320 kDa and large isoform, a mass of 359 kDa. A sequence of 22 amino acids can be found called Ki-67 motif, which includes the epitope (FKEL) targeted by original Ki-67 antibody and is highly conserved between species. In the carboxy terminal region of the molecule, a potential ATP/GTP site was predicted called P-loop. The antigen is exclusively detectable in the nuclei of the cells during interphase. [40]

It plays a critical role in cell division and thought to be required for maintaining cell proliferation, DNA metabolic process, cellular response to heat, meiosis, and organ regeneration. The difficulties in determining the functional role of Ki-67 is due to the absence of similarity with other proteins. Until recently, no protein except some Ki-67 equivalents in other mammals exhibits obvious homology with the human Ki-67, although the presence of conserved domains shared with proteins of characterized functions. [41]

Throughout the cell cycle, the expression of Ki-67 varies in intensity. This shows that it could lead to a misclassification of cycling cells as resting ones. During G1 and early S-phase, the levels of Ki-67 are low, during mitosis progressively increase to maximum level while, during anaphase and telophase, a rapid decrease in expression starts. The degree of expression can be used as a marker of different conditions of growth. Ki-67 has a half-life cycle of around 60-90 minutes. During cell cycle, the differences in expression are due to variable de-novo synthesis not due to the accumulation of nondegraded protein. Throughout the cell cycle, the location and cellular appearance is not homogenous. [42]

Within the growth fraction of given population, the expression of the Ki-67 is thought to be an indicator that the fraction of cells born into the proliferative category. A proliferation marker cannot predict the actual division of the cell, but can be used only to indicate the potential of certain cell to divide. [43] Methods that are mostly used in experimental research are for ethical and practical reasons difficult to apply to human. In contrast, Ki-67 immunostaining can be performed on various types of histological and cytological preperations and is more sensitive and rapid. One drawback is that formalin-fixed paraffin sections, which are routinely used in histopathology, could not be used for the original Ki-67 antibody. [44]

Cyclin D1

G1/S-specific cyclin D1 also called Bcl-1 and PRAD1 oncogene is a protein in human that is encoded by the CCND1 gene. It consists of 295 amino acids with molecular weight of about 34 kDa and is located on chromosome 11q 13.3 . CCND1 contains 5 exons and spans approximately 15 kb. Cyclin D1 belongs to cyclin family, whose members are characterized by periodicity in protein abundance during the cell cycle. [45]

After the discovery of CDK in yeast, now in human genome, more than 13 CDKs and 25 proteins have been identified with homology in the cyclin box, a region of 100 amino acids near the amino terminal. The CDKs form dimmers with different regulatory subunits called cyclins. Among these cyclins, cyclin D1 is the most important for its role in tumorigenesis. [46]

By alternative splicing two transcripts are formed, transcript a and b. Cyclin D1b encoded by transcript b contains 274 amino acids and different C-terminus domain from cyclin D1a. [47] Transcript b expressed in breast cancer cell lines and primary tumors, but at very low levels than transcript a. In breast cancer samples, overexpression of cyclin D1 is primarily accounted for by transcript a. In primary breast cancers, the relative levels of cyclin D1a and cyclin D1b proteins isoforms have not been reported so far. [48]

Cyclin D1 is very important in the development of neoplasia. It is an established oncogene for which the amplification and genomic rearrangement leading to overexpression is commonly found in multiple types of human cancer. In the cyclin D1 gene, these tumor-specific alterations reflect the critical selective advantage conferred by it's over expressed gene product and shows the importance of cyclin D1 in neoplastic process. There is uncertainty about the precise downstream cellular mechanisms that lead to neoplasia by dysregulated cyclin D1. [49] Strong evidence emphasizes that in human breast cancer cyclin D1 overexpression and amplification act as a driving force. Three- to ten-fold amplification of DNA on 11q 13.14 to 11q 13.5 is present in approximately 13% to 20% of the breast cancers. [50]

Cyclin E

Cyclin E is a G1 cyclin which was first identified in 1991. It is located on chromosome 19q 13.1 containing 395 amino acids and molecular weight of 45 kDa. During the cell cycle, the cyclin E levels are periodic and its level is maximum during G1 phase with maximum enzymatic function of cyclin E-cdk2 complex. [51]

It regulates the cell transit from G1 phase to the S-phase of the cell cycle. In the nucleus, the cyclin E accumulates at the G1/S phase boundary and as cell progress through the S-phase it is degeraded. In cancer this firm regulation of cell growth by cyclin is lost. [52] In many breast cancers, the cyclin E is constitutively present in complex with cyclin-dependent kinase 2. This can lead to elimination of important checkpoint control and phosphorylation of substrates at inappropriate times during the whole cell cycle phases. Deregulation of cyclin E causes accelerated S-phase entry, genetic instability and tumorigenesis. It has been shown that in human mammary epithelial cells overexpression of cyclin E induces chromosomal aneuploidy. [53]

In the mid-1990s, the critical role of cyclin E in regulating G1 to S-phase was confirmed by two studies. In one study, constitutive overexpression of cyclin E resulted in diminished requirement for growth factors, decrease in cell size and shortening of the G1 phase. [54] In the other study, it was found that during G1 phase the microinjection of anti-cyclin E antibody into fibroblast resulted in cell cycle arrest. [55] In some breast cancer cell lines, the cyclin E gene is amplified. This amplification can results in constitutively overexpression of cyclin E mRNA throughout the cell cycle up to 64-fold. This overexpression results in chromosomal instability which provides strong support for the role of cyclin E in breast cancer. [56]

Posttranslational cleavage of full-length cyclin E results into low molecular weight forms that are more hyperactive than full-length protein. In addition to overexpressing the 50 kDa full-length cyclin E protein, some breast cancer cell lines express up to five low molecular weight isoforms of cyclin E which are unique to tumor cells. These are related to the increasing grade and stage of breast cancer. [57]


 > Future prospective Top


As breast cancer is a heterogeneous disease with different risk profiles, biological behavior, molecular profiles, and several subtypes, it poses a challenge for its management. Prognostic and predictive biomarkers provide an important tool for individualized therapies and efficient treatment. Some biomarkers such as p53, BRCA1, and HER2 have proved clinical applicability, but there is still need to overcome the deficiencies in the methodologies of their assessment. More tools are required to facilitate clinical decision-making processes in the early stages. There is a need to pay attention on the design and conduct of clinical trials and for the validation of emerging biomarkers for clinical use and reterospective evaluation. With the effort being exploited in characterizing the molecular features of individual cancer and discover of new biomarkers with promising use in clinics, we would able to find unique case-specific patterns of biomarkers, to help in optimization of tailored therapies and breast cancer patient care at individualized level.

Acknowledgments

We are thankful to the National Institute for Biotechnology and Genetic Engineering for the technical support.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
 > References Top

1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.  Back to cited text no. 1
    
2.
Butt Z, Haider SF, Arif S, Khan MR, Ashfaq U, Shahbaz U, et al. Breast cancer risk factors: A comparison between pre-menopausal and post-menopausal women. Breast Cancer 2012;62:120-124.  Back to cited text no. 2
    
3.
Yasmeen F, Zaheer S. Functional time series models to estimate future age-specific breast cancer incidence rates for women in Karachi, Pakistan. J Health Sci 2014;2:213-21.  Back to cited text no. 3
    
4.
Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012;38:698-707.  Back to cited text no. 4
    
5.
Ullah MF, Aatif M. The footprints of cancer development: Cancer biomarkers. Cancer Treat Rev 2009;35:193-200.  Back to cited text no. 5
    
6.
Cracowski JL. Towards prognostic biomarkers in pulmonary arterial hypertension. Eur Respir J 2012;39:799-801.  Back to cited text no. 6
[PUBMED]    
7.
Tainsky MA. Genomic and proteomic biomarkers for cancer: A multitude of opportunities. BBA Rev Cancer 2009;1796:176-93.  Back to cited text no. 7
    
8.
Lee DS, Kim SH, Suh YJ, Kim S, Kim HK, Shim BY. Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy. Jpn J Clin Oncol 2011;41:854-66.  Back to cited text no. 8
    
9.
Hosoda M, Yamamoto M, Nakano K, Hatanaka KC, Takakuwa E, Hatanaka Y, et al. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 2014;144:249-61.  Back to cited text no. 9
    
10.
Lane DP, Brown CJ, Verma C, Cheok CF. New insights into p53 based therapy. Discov Med 2011;12:107-17.  Back to cited text no. 10
    
11.
Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochem Pharmacol 2010;80:724-30.  Back to cited text no. 11
    
12.
Smeenk L, Lohrum M. Behind the scenes: Unravelling the molecular mechanisms of p53 target gene selectivity (Review). Int J Oncol 2010;37:1061-70.  Back to cited text no. 12
    
13.
Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006;124:207-19.  Back to cited text no. 13
    
14.
Wright PE, Dyson HJ. Intrinsically disordered proteins in cellular signalling and regulation. Nat Rev Mol Cell Biol 2015;16:18-29.  Back to cited text no. 14
    
15.
Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A. TP53 status and response to treatment in breast cancers. Biomed Res Int 2011;2011:1-9  Back to cited text no. 15
    
16.
Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: Hubs and spokes in tumor suppression. Cell Death Differ 2010;17:901-11.  Back to cited text no. 16
    
17.
Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.  Back to cited text no. 17
    
18.
Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-65.  Back to cited text no. 18
    
19.
Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. Int J Proteomics 2011;2011:343582.  Back to cited text no. 19
    
20.
Gutierrez C, Schiff R. HER2: Biology, detection, and clinical implications. Arch Pathol Lab Med 2011;135:55-62.  Back to cited text no. 20
    
21.
Aratake J, Suzuki E, Uehiro N, Nishie M, Kawaguchi K, Sato F, et al. Trogocytosis of HER2 overexpressing human breast cancer cell lines may induce its dormancy without depending on HER family signal. Cancer Res 2014;74:1092.  Back to cited text no. 21
    
22.
Kaufmann R, Müller P, Hildenbrand G, Hausmann M, Cremer C. Analysis of Her2/neu membrane protein clusters in different types of breast cancer cells using localization microscopy. J Microsc 2011;242:46-54.  Back to cited text no. 22
    
23.
Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 2012;9:16-32.  Back to cited text no. 23
    
24.
Faltus T, Yuan J, Zimmer B, Krämer A, Loibl S, Kaufmann M, et al. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004;6:786-95.  Back to cited text no. 24
    
25.
Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 2012;118:908-13.  Back to cited text no. 25
    
26.
de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014;15:1137-46.  Back to cited text no. 26
    
27.
Murphy CG, Fornier M. HER2-positive breast cancer: Beyond trastuzumab. Oncology (Williston Park) 2010;24:410-5.  Back to cited text no. 27
    
28.
Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol 2015;1:306-13.  Back to cited text no. 28
    
29.
Rosen EM, Fan S, Ma Y. BRCA1 regulation of transcription. Cancer Lett 2006;236:175-85.  Back to cited text no. 29
    
30.
O′Donovan PJ, Livingston DM. BRCA1 and BRCA2: Breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010;31:961-7.  Back to cited text no. 30
    
31.
Haroun I, Graham T, Poll A, Sun P, Hill K, Weitzner E, et al. Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer. Breast 2011;20:254-8.  Back to cited text no. 31
    
32.
Narod SA. BRCA1 and BRCA2 in 2005. Discov Med 2005;5:50-4.  Back to cited text no. 32
    
33.
Ewald IP, Izetti P, Vargas FR, Moreira MA, Moreira AS, Moreira-Filho CA, et al. Prevalence of the BRCA1 founder mutation c. 5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome. Hered Cancer Clin Pract 2011;9:12.  Back to cited text no. 33
    
34.
Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A 2014;111:14205-10.  Back to cited text no. 34
    
35.
Chen C, Opazo JC, Erez O, Uddin M, Santolaya-Forgas J, Goodman M, et al. The human progesterone receptor shows evidence of adaptive evolution associated with its ability to act as a transcription factor. Mol Phylogenet Evol 2008;47:637-49.  Back to cited text no. 35
    
36.
Gao X, Nawaz Z. Progesterone receptors - Animal models and cell signaling in breast cancer: Role of steroid receptor coactivators and corepressors of progesterone receptors in breast cancer. Breast Cancer Res 2002;4:182-6.  Back to cited text no. 36
    
37.
Anderson E, Clarke RB. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia 2004;9:3-13.  Back to cited text no. 37
    
38.
Brisken C. Reply to is progesterone a neutral or protective factor for breast cancer? Nat Rev Cancer 2014;14:146.  Back to cited text no. 38
    
39.
Denkert C, von Minckwitz G. Reply to Ki67 in breast cancer: A useful prognostic marker! Ann Oncol 2014;25:542-3.  Back to cited text no. 39
    
40.
Saraste M, Sibbald PR, Wittinghofer A. The P-loop - A common motif in ATP- and GTP-binding proteins. Trends Biochem Sci 1990;15:430-4.  Back to cited text no. 40
    
41.
Dingwall C, Laskey RA. Nuclear targeting sequences - A consensus? Trends Biochem Sci 1991;16:478-81.  Back to cited text no. 41
    
42.
Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-20.  Back to cited text no. 42
    
43.
Zarrouki B, Benterki I, Fontés G, Peyot ML, Seda O, Prentki M, et al. Epidermal growth factor receptor signaling promotes pancreatic ß-cell proliferation in response to nutrient excess in rats through mTOR and FOXM1. Diabetes 2014;63:982-93.  Back to cited text no. 43
    
44.
Knutsvik G, Stefansson IM, Aziz S, Arnes J, Eide J, Collett K, et al. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: A population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS One 2014;9:e112121.  Back to cited text no. 44
    
45.
Abraham RT, VanArsdale T, Shields DV, Lee NV, Koehler M, Arndt K. Abstract SY34-03: Braking the cycle: Inhibition of the cyclin D-Cdk4/6 pathway in breast cancer. Cancer Res 2014;74 19 Supplement: SY34-03.  Back to cited text no. 45
    
46.
Reid RJ, Du X, DIttmar JC, Rayannavar V, Sunjevaric I, Maurer M, et al. A synthetic genetic interaction screen in yeast identifies Plk1 as a promising therapeutic target in cancer cells that overexpress Cks1b. Cancer Res 2014;74 19 Supplement: 5088.  Back to cited text no. 46
    
47.
Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11:1005-11.  Back to cited text no. 47
    
48.
Hosokawa Y, Gadd M, Smith AP, Koerner FC, Schmidt EV, Arnold A. Cyclin D1 (PRAD1) alternative transcript b: Full-length cDNA cloning and expression in breast cancers. Cancer Lett 1997;113:123-30.  Back to cited text no. 48
    
49.
Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23:4215-24.  Back to cited text no. 49
    
50.
Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 2014;20:3379-83.  Back to cited text no. 50
    
51.
Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, et al. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 1992;257:1689-94.  Back to cited text no. 51
    
52.
Hunt KK, Keyomarsi K. Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol 2005;15:319-26.  Back to cited text no. 52
    
53.
Willmarth NE, Albertson DG, Ethier SP. Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells. Breast Cancer Res 2004;6:R531-9.  Back to cited text no. 53
    
54.
Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993;259:1908-12.  Back to cited text no. 54
    
55.
Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995;15:2612-24.  Back to cited text no. 55
    
56.
Sgambato A, Zhang YJ, Arber N, Hibshoosh H, Doki Y, Ciaparrone M, et al. Deregulated expression of p27(Kip1) in human breast cancers. Clin Cancer Res 1997;3:1879-87.  Back to cited text no. 56
    
57.
Rogers S, Gloss BS, Lee CS, Sergio CM, Dinger ME, Musgrove EA, et al. Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells. Cell Div 2015;10:1.  Back to cited text no. 57
    



 
 
    Tables

  [Table 1]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Abstract>Introduction>Emerging biomarkers>Future prospective>Article Tables
  In this article
>References

 Article Access Statistics
    Viewed4709    
    Printed78    
    Emailed1    
    PDF Downloaded476    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]